The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).
 
Sukeshi Patel Arora
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Exelixis (I)
Research Funding - BeiGene; Halozyme; Lexicon; Lilly
 
Laura LaNiel Tenner
Consulting or Advisory Role - Bayer; Community First Health Plans; New B Innovation
Travel, Accommodations, Expenses - Bayer; New B Innovation
 
John Sarantopoulos
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Fulgent Genetics; Genentech/Roche; Immunocore; Merck; Novartis; Pfizer; Sun Pharma; Takeda
 
Jay Larry Morris
No Relationships to Disclose
 
Lisa Longoria
No Relationships to Disclose
 
Qianqian Liu
No Relationships to Disclose
 
Joel Michalek
No Relationships to Disclose
 
Devalingam Mahalingam
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Eisai; Genentech
Research Funding - Merck; Oncolytics
Expert Testimony - Blake Jones Law Firm